conference that will make the case for Cosentyx (secukinumab) in a highly competitive market. Cosentyx is a key drug for Novartis, as it is part of the company’s plan to replace lost sales from ...

It is a potential competitor to Novartis’ blockbuster Cosentyx (secukinumab) and clinical evidence for its use in dermatology and rheumatology is already stacking up. There was little indication ...